Podcasts about Bayer

In this episode of the Programmatic Digest, host Ellen Parker welcomes two of LinkedIn's most active programmatic voices: Gary Guarnaccia and Ryan Verklin. Together, they dive into the realities of in-housing, retail media, DSP strategy, and the ongoing shifts in supply path optimization (SPO). Ryan shares his journey from agency life to in-house at Bayer, where he helped lead the transition to hands-on programmatic buying before moving into retail media. Gary reflects on his role supporting Bayer's in-house teams through ad tech partnerships, ensuring programmatic and retail investments drive real business outcomes. We dig into hot-button industry debates, including: In-house vs. agency vs. retail media networks – how traders' roles are evolving. DSP strategy – why more DSPs don't automatically mean more reach. Retail media networks – the difference between on-site and off-site, and how CPG brands leverage retailer data for incremental reach. Amazon DSP – is it really positioned to replace other omni-channel platforms? Traders' perspective – why user-friendly DSPs, efficient reporting, and reduced friction are critical to long-term success. SPO and transparency – reacting to Index Exchange's announcement and The Trade Desk's move to categorize SSPs as resellers. The conversation highlights a recurring theme: programmatic traders need more love. Empowering the hands-on-keyboard teams with better tools, education, and collaboration leads to stronger business results—and less burnout. If you're a programmatic trader, strategist, or leader navigating the complexities of DSPs, SSPs, and retail media, this episode is packed with insights and candid perspectives you won't want to miss. Additional resource: Gary LinkedIn post    About Us: We teach historically excluded individuals how to break into programmatic media buying and land their dream jobs. Through our Reach and Frequency® program, an engaged community, and expert coaching, we offer:   Programmatic Training & Coaching: Executive Membership: for the busy mid-level to senior or director-level programmatic ninja looking for a structured, high-impact way to stay ahead of evolving trends, sharpen your optimization skills, and connect with like-minded experts. Join Here: https://programmaticdigest14822.ac-page.com/executivemembership   Accelerator Program: A 6-week structured program with live coaching, hands-on DSP exercises, and real-time feedback. Sign Up: https://reachandfrequencycourse.thinkific.com/courses/program   Self-Paced Course: Learn at your own speed with full content access. Enroll Here: https://reachandfrequencycourse.thinkific.com/bundles/the-reach-frequency-full-course   Timestamps 00:00 – Welcome & Guest Introductions 03:11 – From Agency to In-House: Ryan & Gary's Journeys 08:35 – The Rise of Retail Media at Bayer 14:20 – DSP Strategy: Why More Doesn't Always Mean Better Reach 20:02 – Retail Media Networks: On-Site vs. Off-Site Explained 26:41 – Amazon DSP: Threat or Opportunity? 33:17 – Why Traders Deserve More Love in Ad Tech 40:05 – Reporting, AI, and Reducing Friction for Traders 46:28 – SPO Debate: Resellers, Transparency & Control 53:19 – Final Thoughts & Industry Takeaways   Meet Our Guest: Gary Guarnaccia – Ad Tech Partnerships, Bayer https://www.linkedin.com/in/gary-g-16328640/   Ryan Verklin – Retail Media Lead, Bayer https://www.linkedin.com/in/verklin/ https://www.instagram.com/verklin/ https://x.com/verklin   Meet The Team: Hélène Parker - Chief Programmatic Coach https://www.heleneparker.com/  https://www.linkedin.com/in/helene-parker   Manuela Cortes - Co-Host  Programmatic Digest In Espanol:  https://www.linkedin.com/in/manuela-cortes-   Learn Programmatic As a TEAM: https://www.heleneparker.com/workshop/ As a Programmatic Ninja: https://www.heleneparker.com/course/ Programmatic Coaching Newsletter:https://www.heleneparker.com/newsletter/   Programmatic Digest https://www.linkedin.com/company/programmatic-digest-podcast https://www.youtube.com/channel/UCBGMMRsZkw0IIUbQIJmMBxw   Looking for programmatic training/coaching?  Sign up to our Accelerator Program: A 6-week structured program with live coaching, hands-on within DSP(s) exercises, and real-time feedback—perfect for those who thrive on accountability and community, and looking to grow their technical skillset https://reachandfrequencycourse.thinkific.com/courses/program   Self-Paced Course: Full access to course content anytime, allowing independent learners to study at their own speed with complete flexibility. https://reachandfrequencycourse.thinkific.com/bundles/the-reach-frequency-full-course   Join our next workshop by signing up to our waitlist below:  https://www.heleneparker.com/waitlist/  

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die KI-FOMO-Rallye, eine aufschlussreiche Tesla-Rechnung und einen neuen Rekord bei Siemens Energy. Außerdem geht es Siemens, Siemens Healthineers, BASF, Tesla, Alphabet, Apple, Nvidia, Kodiak AI, Rheinmetall, Carl Zeiss Meditech, Jenoptik, Nordex, Intershop, Halloren, Merck, Bayer, Fair Isaac, Strategy, Bitcoin, Ether, Solana, Occidental Petroleum und Berkshire Hathaway. iShares Core MSCI World ETF (WKN: A0RPWH), Invesco EQQQ Nasdaq-100 ETF (WKN: 801498), iShares Core Dax ETF (WKN: 593393), Xtrackers MSCI World ex USA (WKN: DBX0VH). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Gamechanger-Deal, Wall-Street-Rekorde trotz Shutdown und das fulminante Börsendebüt von Fermi. Außerdem geht es um Pfizer, Merck, Eli Lilly, Novo Nordisk, Vertex, Regeneron, Thermo Fisher, Repligen, Danaher, Boston Scientific, Abbott, Intuitive Surgical, Bayer, Merck, Salzgitter, Thyssenkrupp, Bitcoin, Solana, Ether, Sartorius, Palantir Technologies, Thales, L3Harris Technologies, RTX, Kratos Defense & Security Solutions, AeroVironment, DroneShield, Elbit Systems, Electro Optic Systems, Saab AB, Hensoldt, Mercury Systems, QinetiQ, Chemring Group, Cohort, Exail Technologies, Rocket Lab, Iridium Communications, BlackSky Technology, Electro Optic Systems, Leidos Holdings, CACI International, Parsons, Telos Corp, Leidos, SAIC, QinetiQ, Parsons VanEck Space Innovators ETF (WKN: A3DP9J), Invesco Defence Innovation ETF (WKN: A40J95), Global X Defence Tech ETF (WKN: A40E7A), Droneshield, Palantir, Red Cat Holdings. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this Phil-Ins episode of “Buy: The Way…To Purposeful Procurement,” Philip Ideson, Rich Ham, and Kelly Barner reflect on their conversations with Bayer CPO Thomas Udesen, franchise procurement leader Kristine Morton, and procurement entrepreneur Jason Busch. Despite differences in scope, scale, and sector, the through-line is unmistakable: common sense.  For example, Thomas showed how Bayer abandoned “pointless” savings metrics in favor of measures that connect directly to business outcomes, while Kristine reminded us that for franchisees, if it doesn't hit the P&L, it didn't happen. And Jason revealed how AI employees could finally make real-time validation and continuous monitoring of results possible at scale. Taken together, these stories underscore procurement's most pressing challenge: leaving behind the dysfunctional obsession with “claimed savings” and building incentive systems that reward real impact. Rich, Phil, and Kelly also step back to examine procurement's sense of alignment (or detachment?) from the wider business. Kelly shares vivid experiences from her own practitioner days, contrasting the urgency of grocery logistics with the abstraction of office supplies. Phil cautions against “procurement blinkers,” reminding us that silos plague every function, not just ours. And Rich argues that measuring against EBITDA – profits, not projections – may finally put procurement “on the pitch” with their teammates. This recap sets the stage for the next phase of the series: designing incentive structures that actually work. Because if procurement doesn't align with business value, AI vendors may sell that value straight to the C-suite. Links: Rich Ham on LinkedInLearn more at FineTuneUs.com

Der BVB setzt sich trotz Rotation souverän gegen Bilbao durch. Leverkusen kann auch gegen Eindhoven nicht gewinnen und hat nun keine gute Ausgangslage mehr in der Champions League. Außerdem schauen wir auf die Euro-Spiele von Stuttgart, Freiburg und Mainz.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die großen Verschiebungen im 3. Quartal, Trumps wirren Deal mit Pfizer und Wolfspeed, die wie Phoenix aus der Asche steigen. Außerdem geht es um Applovin, Western Digital Corp, Warner Bros, Seagate Technologies, Intel, Tesla, Charter Communications, Trade Desk, Lululemon, FactSheet, Molina Healthcare, Gartner, Commerzbank, Deutsche Bank, BMW, Airbus, Fresenius, Bayer, Deutsche Börse, Symrise, Beiersdorf, Lithium America, Berkshire Hathaway, Occidental Petroleum, Nike, Adidas, Puma, Electronic Arts, MoonLake Immunotherapeutics, Insmed Incorporated, Madrigal Pharmaceuticals, Krystal Biotech, Mineralys Therapeutics, Vera Therapeutics, Summit Therapeutics, TripAdvisor, Zoom Communications, Unity Software, Workiva, Trimble, Take-Two Interactive Software, Avepoint, Groupon, Magnolia Oil, Kinetik Holdings, Kosmos Energy, Parsons Corporation, Hexcel Corporation, Science Applications International, Kratos Defense & Security Solutions, Scout24, Brenntag, Hugo Boss, Nordex, Temenos, Avolta, Burberry, Remy Cointreau, Whitbread, Reckitt Benckiser, Amadeus IT Group, Moncler, Signify, Iveco Group, EDP Renovaveis, Solaria Energia, Novo Nordisk, Eli Lilly, Vanguard FTSE All-World ETF (WKN: A2PKXG). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this virtual podcast with Bayer, GaryVee shares his perspective on how AI, data, and shifting consumer attention are reshaping the future of healthcare and business. He discusses why brand and trust matter more than ever, how large organizations can stay innovative, and what leaders need to focus on to adapt in 2025 and beyond. A practical and forward-looking conversation for anyone interested in the intersection of business, technology, and healthcare.

Fr. Pat Driscoll discusses the intricacies of Guardian Angels, Andrea Picotti Bayer on holy women stepping up in times of crisis, and Edward Pentin on the Catholic Faith in the United Kingdom.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally. Cilento speaks to the advancement from GenAI to agentic AI, what's changed for his own team in this regard and what's required by way of a culture shift more generally, as well as speaking to the changes necessary in the advanced therapies space when it comes to commercialisation. You can listen to episode 206a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

As combines roll across the Prairies, harvest offers more than just a chance to bring in the crop; it’s also the perfect time to look across fields and asking what went right, what could be improved, and how to set up for success in 2026. Tim Darragh, canola technical strategy lead with Bayer, says one... Read More

Es ist ja wie es ist, wenn wir verlieren und Tim mit der Schiedsrichterleistung nicht zufrieden ist: Wir haben erhöhten Redebedarf. Mit Nina und Maik geht es also um das Spiel gegen Bayer 04 Leverkusen, strittige Entscheidungen von Martin Petersen und die anstehende Redaktionswoche vor unserem Auswärtsspiel bei Werder Bremen. Titelfoto: Stefan Groenveld

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript. Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO editorial fellow, and today I am joined by Dr. Martin Wermke, Professor for Experimental Cancer Therapy at Dresden University of Technology, to discuss the manuscript “Phase 1 Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-like T-Cell Engager Obrixtamig in Patients with DLL3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.” Obrixtamig is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T-cells. This manuscript presents the phase 1A dose escalation results of Obrixtamig in patients with DLL3+ small cell lung cancer and neuroendocrine carcinomas. In this study, 168 patients were treated with Obrixtamig across four different dosing regimens. 49% of the patients had small cell lung cancer, 42% had extrapulmonary neuroendocrine carcinoma, and 8% had large cell neuroendocrine carcinoma of the lung. Patients received a median of two prior lines of therapy. 33% of the patients had brain metastases at baseline. Of note, this trial did not mandate baseline brain imaging. Maximum tolerated dose was not reached. 88% of the patients experienced a treatment-related adverse event, however, only 3.6% of the patients had to discontinue treatment due to treatment-related AEs, and dose reduction due to treatment-related AEs was documented in 2.4% of the patient population. Similar to the other DLL3-targeted bi-therapies, the most common adverse events included CRS in 57%, dysgeusia in 23%, and pyrexia in 21% of the patients. CRS events were mostly mild. They occurred more frequently in the first two to three doses. 9% of the patients experienced ICANS, of which 3% were graded as Grade 3 or higher. And let's review the efficacy results. Responses were only seen in patients who received 90 microgram per kg or more once weekly or once every three weeks dosing. The objective response rate in patients who received an effective dose was 28%. If we review by tumor type, 21% of the small cell lung cancer patients, 27% of the extrapulmonary neuroendocrine carcinoma patients, and 70% of the large cell neuroendocrine carcinoma patients had objective response. Median duration of response was 8.5 months, though this data is immature due to short follow-up. Dr. Wermke, DLL3-targeted bispecific T-cell engagers are reshaping the treatment landscape of small cell lung cancer. This trial investigates Obrixtamig in other high-grade neuroendocrine tumors as well. Can you put this trial into context for us and explain why it may represent an important step forward? Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to discuss our data today. I think the data with Obrixtamig in small cell lung cancer are largely similar to what has been observed with other bispecific T-cell engagers such as tarlatamab with respect to the response rate and duration. It has, however, been to be mentioned that BI 1438001 had a bit more liberal inclusion criteria than other trials around. You already mentioned the fact that we allowed the inclusion of patients without mandatory brain imaging, which led to some patients having their brain mets been diagnosed during the treatment with obrixtamig and then adding to the progressive disease patients. That is something which was not the case with the tarlatamab trials where you really had to have a brain imaging before, and in the Phase 1 trial you were even required to treat the brain mets before you included the patient. So it is a bit different, more poorest patient population. I think the trial adds on existing data by being the first trial to also include non-SCLC neuroendocrine carcinoma of other origin, for example from the gastrointestinal tract, and also by including large cell neuroendocrine carcinoma of the lung, which is a really hard to treat pulmonary neoplasm which currently lacks any standardized treatment. So that is really a step forward which we will build on in the future. Dr. Ece Cali: And one thing I would note in this trial, only patients with tumor expressing DLL3 were enrolled. Can you tell us a little bit more about this target, DLL3 in the context of neuroendocrine tumors, and does DLL3 expression predict clinical outcomes after treatment with DLL3 BiTEs, or do we actually need other predictive biomarkers for these novel agents? Dr. Martin Wermke: Yeah, thank you. That's a pretty interesting question. First of all, DLL3 is an atypical notch ligand, which is expressed by the majority of neuroendocrine carcinomas, virtually absent on healthy adult tissues. Therefore, turning it really into a bona fide target for T-cell engaging therapies, pretty low risk for on-target off-tumor side effects. We found that in all the patients we screened, we had an expression rate of about 94% in small cell lung cancer, 80% of large cell neuroendocrine carcinoma of the lung were positive, and also about 80% of the extrapulmonary neuroendocrine carcinoma. So it's really a high prevalence. So the fact that we only included DLL3+ tumors still means we included most of the patients that presented with these diseases. I think at the moment there are no data suggesting a clear-cut association between DLL3 expression levels and outcome on DLL3 CD3 T-cell engagers. There's also not a lot published. If you want to find this out for tarlatamab, you have to look into their patent to really see the data, but it's not clear-cut and I'm sure we need other markers to complement that. And I think what probably plays a major role is intrinsic T-cell fitness. So the question how really diseased your T-cells are, how old you are, because age also correlates with the fitness of the immune system, and other patient characteristics such as tumor burden, we've seen all across the board that the higher the tumor burden, the lower the rate of prolonged response is in such trials. And I also think we need to focus on other components of the tumor microenvironment. So see how high the T-cell infiltration with obrixtamig is and how abundant suppressive elements like regulatory T-cells or myeloid-derived suppressive cells are. That is work which is currently being done. Data are emerging, but I don't think that at the moment we have any clear biomarker helping us to select who should not receive DLL3 T-cell engagers. Dr. Ece Cali: Those are great points and there is a lot we need to learn about how to use these novel agents in the future. I'd like to highlight the results in large cell neuroendocrine carcinoma of the lung. The response rate in this group was remarkably high at 70%. Though we should note the small sample size of only 14 patients in this trial. After first line chemoimmunotherapy, current approved options for this population have very modest clinical activity. Given these trial results, how do you envision the field moving forward for patients with large cell neuroendocrine carcinoma? Dr. Martin Wermke: Yeah, I think LCNEC is really an area which urgently needs further improvement of therapeutic standards. At the moment, as I said, there is no real standard. We are usually extrapolating from results we have in small cell lung cancer or non-small cell lung cancer, but I don't think we have too many prospective trials really informing this. Of course, 14 patients is a small sample size, but I think it's still fair to say that we can claim that DLL3 T-cell engagers are not doing worse in LCNEC than they do in SCLC. And that's why I think we really need to move forward clinical trials that are specifically targeting this population. Although I fear a bit that, given the rareness of this disease and the aggressiveness of its phenotype, that this is probably not the main focus of the pharmaceutical industry. So I think it's up to us academic investigators to really come up with investigator-initiated trials trying to fill the knowledge gaps we have here. Dr. Ece Cali: And one more thing that I want to talk about is the accessibility for these drugs. These novel agents are showing real promise in improving outcomes for patients with high-grade neuroendocrine tumors, an area where progress has been limited until very recently. However, as DLL3 BiTEs become more widely used, issues of logistics and access come into sharper focus. With unique toxicities and the specialized monitoring, their use is restricted to certain centers. Looking ahead, what kinds of strategies could help mitigate some of these adverse events or make these treatments more broadly available? Dr. Martin Wermke: Yeah, I think if you look at countries like the United States where tarlatamab has already been approved, we can see how the management strategies are evolving. I've heard about a colleague equipping their patients with thermometers and a pill of Dexamethasone, alongside with a temperature control protocol and clearly instructing them, "If you measure a temperature above a certain level then start taking the Dexamethasone and come back to our office and we're going to take care of you." I think that's one way to move forward. I think we are lucky in a way that CRS usually manifests within the first 24 hours. This was the same in our study, like in the tarlatamab studies. So we really know when the time of trouble is for our patients. And in this time, I think we need to instruct the patients to stay close to the hospital. I don't think we need to hospitalize all of them, but we probably need them to stay in a nearby hotel to be able to reach the emergency room if needed in a short period of time. And I think we can also learn in this strategy how to manage bispecific antibodies from the experience our colleagues in hematology had because they have been using bispecific T-cell engagers for quite some years right now and they developed strategies and networks that were able to successfully treat these patients also on an outpatient basis. And I think that is clearly an experience we need to follow, acknowledging that we are talking about diseases which are much more frequent than the standard hematology indications. Dr. Ece Cali: Thank you so much, Dr. Wermke, for this informative discussion and for sharing your perspective on this evolving field. Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to talk about data. It was really great being able to share that, and I really think that we are just at the beginning of a new exciting area for the treatment of neuroendocrine carcinomas, and I think much improvement is yet to come for our patients. Dr. Ece Cali: Yes, that's really exciting. And thank you everyone for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Martin Wermke's Disclosures Honoraria: Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT, Amgen, Novartis, Pfizer,  BMS GmbH & Co. KG, Regeneron, MJH/PER, Takeda Consulting or Advisory Role: Bristol-Myers Squib, Novartis, Lilly, Boehringer Ingelheim, ISA Pharmaceuticals, Amgen, immatics, Bayer, ImCheck therapeutics, AstraZeneca, Tacalyx, Regeneron, Daiichi Sankyo Europe GmbH, Zymeworks, PharmaMar, Iovance Biotherapeutics, T-Knife, Genentech Research Funding: Roche Patents, Royalties, Other Intellectual Property Travel, Accommodations, Expenses: Pfizer, Bristol-Myers Squibb, AstraZeneca,  Amgen,  GEMoaB, Sanofi/Aventis, immatics,  Merck Serono, Janssen Oncology, Iovance Biotherapeutics, Daiichi Sankyo Europe GmbH"

+++ 0:1 Tapsoba (25. Minute, ohne Vorarbeit) +++ 1:1 Wahl (32. Minute, ohne Vorarbeit) +++ 1:2 Poku (58. Minute, Vorarbeit Grimaldo) Zuschauer*innen: 29.546 (ausverkauft)

Josep Codina analiza en profundidad la situación del IBEX 35 a las puertas de la temporada de resultados del tercer trimestre. Con el índice español apuntando a los 16.000 puntos, Codina explica qué valores podrían impulsar el rally y cuáles requieren más cautela. ¿Será suficiente el apoyo de los resultados empresariales para romper resistencias? ¿Qué papel jugarán los bancos, Inditex y Telefónica en este escenario? En este análisis repasamos las claves del mercado: desde el BBVA en zona de máximos históricos, hasta el comportamiento de Banco Sabadell, Telefónica y Banco Santander. También se estudian las perspectivas de Inditex, y en Europa los casos de Bayer y Siemens, mientras que en Wall Street el protagonismo recae en IBM. El vídeo cierra con las previsiones de Josep Codina sobre la evolución técnica del IBEX 35 y los posibles escenarios de corto plazo, con especial atención al objetivo de los 16.000 puntos. Más información: https://www.finanzas.com/inversion/podcasts/ibex-35-20250929/

In this episode, recorded at the #NBF2025, I sit down with Annika Essén-Suuronen, Transformation Lead & DSO Coach at Bayer, to explore one of the boldest corporate transformations happening today. With more than 20 years at Bayer, Annika is now at the forefront of driving the company's shift from a traditional management system to what they call #DynamicSharedOwnership. Dynamic Shared Ownership is about unleashing the full potential of both the organization and its people to create value for all stakeholders. It reimagines the system by prioritizing mission and outcomes over conflicting KPIs, fostering self-directed teams within a flat structure and encouraging co-creation across networks of teams rather than silos. Together we discuss what it means to redesign leadership and decision-making at scale, how Bayer is creating faster learning cycles and a people-centric culture, and what lessons can be drawn from this ambitious journey. Annika also shares her deeply personal story of transformation, which powerfully aligns with the values behind this change. This conversation is both candid and inspiring, offering valuable insights on trust, courage and the human side of organizational transformation. Listen and enjoy …

Cette émission sera une émission spéciale sur des moments spéciaux, ces instants privilégiés dans la vie où l'on rencontre des personnes qui éveillent en nous quelque chose de plus profond que nous-mêmes. C'est ce que j'ai ressenti en rencontrant Boualem Saidi. J'ai passé mon enfance les pieds nus dans les champs d'un village oublié de Dieu. Boualem, lui, a passé son enfance avec les pieds couverts de la poussière maghrébine de l'Afrique du Nord où il a grandi. La vie m'a conduit en France où j'ai étudié le journalisme et travaillé dans les rédactions dont je rêvais en Roumanie. Boualem, quant à lui, a également été amené à Paris, où il a étudié les sciences dures : biologie, mathématiques, physique, chimie… En 2020, il a pris les rênes de la société Bayer en Roumanie, Bulgarie et Moldavie. Boualem a mis les voiles en direction de l'Europe de l'Ouest, mais il laisse en Europe de l'Est des projets qui ont permis à la région où nous nous trouvons de réaliser des bonds économiques extraordinaires. Pour moi, Boualem Saidi reste le meilleur PDG que j'ai rencontré en Roumanie au cours de ma carrière de journaliste. De cet enfant né en Afrique du Nord est sorti un homme intègre, porteur de valeurs qui imposent respect et reconnaissance.

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

On this week's podcast we go through the figures on crop profits, tillage incomes and what's bringing about the best return with Dr Fiona Thorne of Teagasc. We also talk about a new Irish ration on the market. This week's show was recorded live at the National Ploughing Championships. The Tillage Podcast is supported by Bayer crops Science. Hosted on Acast. See acast.com/privacy for more information.

As another year's wheat harvest draws to a close, the country's most progressive farmers are getting ready to submit their crop data to the National Wheat Foundation's annual Wheat Yield Contest. Anne Osborne, Executive Director of the National Wheat Foundation, and her team are preparing to review submissions and crown a new year of bin-busters and quality leaders, but took a break for her preparations to sit down with us on the podcast this week to talk about the history of the contest, what's new for 2025, and what she's expecting for the year ahead.To learn more about the contest, see past winners, and enter, visit https://wheatfoundation.org/wheat-yield-contest/. This edition of Field Posts is brought to you by the National Wheat Foundation in partnership with Bayer, WestBred, BASF, Dyna Gro Seed, and Nutrien Ag Solutions.

JCO PO authors Dr. Abhishek Tripathi and Dr. Salvador Jaime-Casas at City of Hope Comprehensive Cancer Center share insights into their article, “Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma.”  Host Dr. Rafeh Naqash and Drs. Tripathi and Jaime-Casas discuss a novel understanding of the genomic alterations underlying SCBC, revealing actionable mutations that could serve as potential targets for improved clinical outcomes. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, I am thrilled to be joined by Dr. Abhishek Tripathi, Associate Professor in the Department of Medical Oncology and Experimental Therapeutics Research at the City of Hope Comprehensive Cancer Center, as well as his mentee, Dr. Salvador Jaime-Casas, postdoctoral research fellow and first author of the JCO Precision Oncology article entitled "Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared with Urothelial Carcinoma and Small Cell Lung Carcinoma". At the time of this recording, our guest disclosures will be linked in the transcript. Abhishek and Salvador, welcome to our podcast and thank you for joining us today. This is a very interesting topic given that at least the landscape for neuroendocrine carcinomas, where small cell lung cancer is on one end of the spectrum, has been changing, at least on the lung cancer side, with recent approvals and some new ADCs. So, of course, understanding the genomic and transcriptomic similarities or differences between pulmonary small cell and extrapulmonary small cell is of huge interest. Could you tell us a little bit about small cell bladder cancer, current approaches to treatment of small cell bladder cancer, and then why you wanted to investigate that in this project as far as the genomic differences or similarities are concerned? Dr. Salvador Jaime-Casas: Well, first of all, thank you very much for having me. I am very excited to be here. And really what served as backbone for this research project was the notion that there is a currently evolving genomic landscape in the area of bladder cancer. We know this is a highly heterogeneous disease when it comes to molecular underpinnings and mutational profile. Specifically, we know that the most common histologic subtype is urothelial carcinoma. Small cell bladder cancer represents a histology that is found in less than 1% of all bladder cancer cases. However, it is one of the most aggressive histologies. It presents with a very poor prognosis to patients and very poor response to treatment, which is why we attempted to really elucidate what is the mutational profile behind this and provide a comparison contrast between small cell bladder cancer, small cell lung cancer, and conventional urothelial carcinoma. As your question mentioned, in terms of treatment, the conventional urothelial carcinoma and small cell bladder cancer are two distinct pathways when it comes to treatment algorithms. We know that in the current era there are newer and newer drugs being developed for conventional urothelial carcinoma. We have perioperative immunotherapy in the context of metastatic disease. We have antibody-drug conjugates such as enfortumab vedotin. But really, this amazing track record of drug development hasn't been mirrored in small cell bladder cancer. And here most of the therapy is usually extrapolated from studies from other small cell histologies like you mentioned earlier, small cell lung cancer has given some form of background in terms of what therapies are used here. Cytotoxic chemotherapy, for some patients with localized disease and small cell bladder cancer, concurrent chemotherapy and radiotherapy or perioperative cytotoxic chemotherapy have been the cornerstone of treatment for many years now. However, like I mentioned, the oncologic outcomes are very suboptimal when it comes to comparing it with other disease histologies, which is why we really wanted to describe the landscape here and provide this comparison across three different groups. For this particular study, we leveraged the Tempus dataset. So, include patients with urothelial carcinoma with small cell bladder cancer and small cell lung cancer. We included their demographic information, as well as the frequency of most common genomic alterations identified. And really, it was a very comparable Table 1. We see the demographic data across the three groups was very similar. One key thing that we identified was the female prevalence was a little bit lower in patients with small cell bladder cancer when compared to small cell lung cancer. But other than that, the age, race, ethnicity, was comparable across groups, and even the smoking history. Most of the patients in this cohort were former smokers, which we believe comes to explain that regardless of any mutational profile that we talked about in a few minutes, there are shared commonalities between these histologies and shared environmental exposures and risk factors that are going to be implicated in the disease biology for these three histologies. Dr. Rafeh Naqash: Thank you so much, Salvador, for that useful background. I would like to shift to Abhishek real quick. Abhishek, you are a practicing clinician, you have led several studies in the GU space, especially bladder. Based on what you see in the small cell lung cancer space, how drug development is shaping up, which aligns with what you are trying to evaluate in this paper as targets, how do you see some of that being implemented for small cell bladder cancer in the current era and age? Abhishek Tripathi: Thanks so much for the excellent question, Rafeh. As a GU investigator, small cell bladder cancer has always lagged behind in some regards regarding enrollment abilities for the novel clinical trials. And small cell lung cancer has paved the way and led the development of a lot of these drugs across the board. With the most recent sort of drugs targeting DLL3 already approved and several antibody-drug conjugates currently in development. That actually translates really well to how we should approach drug development in bladder cancer. What we saw in the study is that although there are overlaps and similarities between small cell lung cancer and small cell bladder cancer, there are also certain differences. So the long-term assumption that all therapies for small cell bladder cancer can be extrapolated to small cell bladder], may or may not be true, and I think it is high time that we specifically investigate these novel agents in tissue-specific small cell carcinomas. To that effect, we are excited to be participating in trials that are looking at some of the novel DLL3 targeted agents, specifically bispecific antibodies and T cell engagers so to speak, and antibody-drug conjugates that are now starting to open enrollment specifically in non-lung cancer cohorts to evaluate its efficacy. So overall, I think studies like this have the opportunity to identify more putative targets for organ-specific development of these novel agents. Dr. Rafeh Naqash: Absolutely, I could not agree more. I think tumor-agnostic therapies definitely have a place, but not all therapies work the same in different tumors with a similar histological or genomic background because there are definitely differences. So now going to the comparison that Salvador, you guys did in this project, could you help us understand what are some of the things you looked at, what were some of the commonalities and the differences, and what were some of the conceptual thoughts that come out from those results? Dr. Salvador Jaime-Casas: Of course. So, the first thing that we identified was which were the most frequent molecular alterations across these histologies. We actually provided a table showcasing how the most common mutations that we identified were TP53, TERT, RB1. However, like Dr. Tripathi mentioned, the distinction between these histologies is notable in the sense that some are more predominant in small cell-pertaining cancers such as bladder cancer and lung cancer. While some others are more common in bladder-pertaining malignancies like urothelial carcinoma and small cell bladder cancer. For instance, we saw that TP53 and RB1 were significantly more evident in small cell histologies, both small cell bladder cancer and small cell lung cancer, as opposed to conventional urothelial carcinoma, which really this mirrors what is known about these mutations and what has been published. These are markers associated with more aggressive disease with a worse prognosis and even to resistance to treatment. We also identified how TERT mutations were characteristically more prevalent in small cell bladder cancer as opposed to small cell lung cancer, as well as in urothelial carcinoma. TERT mutations were more commonly identified than in small cell lung cancer. And we give a long list of these mutations that we identified, but really what we wanted to underscore here was, A, the most common mutations across histologies; B, the most common co-occurring mutations where we saw that these are not mutually exclusive. A lot of patients had co-occurring TP53 and RB1 or RB1 and TERT or RB1 and ARID1A, really elucidating how heterogeneous this molecular landscape is across histologies. And the third one that we believe really brings down the clinical impact of this research was evidencing the idea of clinically actionable mutations. We also provided a table here showcasing how mutations like FGFR, DLL notch pathway, HER2, were evident in these histologies, and what is the current status of some clinical trials evaluating different drug designs for these mutations. Like Dr. Tripathi mentioned in the context of FGFR, approximately 6% of our cohort with small cell bladder cancer showcased mutations in FGFR3. However, up to 14% of them had mutations in any FGFR gene, which really underscores the notion that drugs like erdafitinib, which have been introduced in the market in recent years, could potentially showcase some response in the space of small cell bladder cancer. We actually provide the description of two trials, phase two, phase three trials, that are evaluating erdafitinib in the context of high-risk non-muscle invasive bladder cancer and even metastatic urothelial carcinoma. Like Dr. Tripathi mentioned as well, antibody-drug conjugates, another very interesting area of drug development targeting HER2, we included evidence on how disitamab vedotin and trastuzumab deruxtecan are currently being explored across different phase two and phase three clinical trials, both as part of basket trial designs for solid malignancies expressing HER2, but also for patients with urothelial carcinoma where there is evidence of HER2 expression. So, we believe that the landscape is shifting in the right direction in the sense that therapies are becoming much more personalized and targeted against these known molecular profiles. Dr. Rafeh Naqash: Thank you, Salvador, for summarizing some of those very interesting results and providing a very unique conceptual context to that. I would like to go to Abhishek this last portion. Of course, I am sure you guys will expand on this work and there are a lot of other interesting things that will likely come out from this work and hopefully you will publish that in JCO PO. But one of the very important things that I wanted to highlight from this podcast specifically was the science is obviously very interesting, but I feel the more important interesting aspect is giving trainees and fellows, residents, mentorship opportunities, mentoring them and giving them lead roles in projects like this, which is what Dr. Tripathi has successfully done for you in this project, Salvador. So, Abhishek, as somebody I have known for a couple of years now, more than a couple of years, as a very successful clinical translational investigator in the GU space in the early phase setting, Abhishek, really briefly, within a minute, could you tell us about your journey and what are some of the things that have worked for you as an early career investigator that you have learned from, and then your journey of mentorship, how has that been for you and what are some of the things that you take home from your mentorship role? Abhishek Tripathi: Absolutely. And as you mentioned, mentorship has been pivotal for all early career investigators for them to really succeed. So, my journey, as you know, I started off as an early career investigator at another institution, and I think I owe it to my mentors even at that time and even now who are helping me develop some of these newer translational and clinical trial ideas, creating opportunities where we could really showcase some of the interesting work that we are doing. That actually goes a long way in terms of creating independence as an established investigator. And I think the sooner we start off with mentorship prospects, I think the better it is. And paying it forward, I think I have been lucky to have mentees like Salvador who are just extremely talented, really committed, and goal-oriented. He really led the project right from the beginning in terms of initial analyses and looking up all the sort of correlative studies that we could do and the contextual data between small cell lung cancer and bladder cancer that we have delved into for the past several years. And it really showcases the ability of young mentees like Salvador to really excel given the right guidance and the support. As a mentor, it has been a really rewarding experience. It is really helpful to actually learn from some of these mentees as well as to approach the same problem from a different angle and different thought process and guide them through the study. So, it has been incredibly helpful and rewarding both being a mentee and a mentor over the past several years as I have transitioned. Dr. Rafeh Naqash: Thank you, Abhishek, for those very insightful comments on how both being a mentee and being a mentor helps shape you as an individual as well. And then you take a lot of pride in the success of your mentees. Now real quick, Salvador, could you tell us a little bit about yourself, you know, how you ended up at City of Hope under Dr. Tripathi's mentorship and what are some of the next important things that you are looking forward to doing? Dr. Salvador Jaime-Casas: So, a little bit about who I am. I did medical school in Mexico City. I was born and raised there, and towards the end of my medical training, I started to be engaged in research projects. And through one of my mentors in Mexico, I was actually introduced to the team here at City of Hope, including Dr. Tripathi. And through this, we got the opportunity to have some conversations about what I wanted to do, become a physician-researcher in the area of genitourinary oncology and hopefully my transition to residency in a few years. And that is how I came to be his mentee here at City of Hope. I think it has been a very rewarding experience, like Dr. Tripathi said, having such an incredible mentor and really being with him both in the academic setting and in the clinical setting, in patients with clinic, seeing this curiosity and all these clinical trials, all of this evidence that we have coming together to generate this insight. Dr. Rafeh Naqash: Thank you so much for both the scientific insights, as well as the journey of being a mentee for you, Salvador, and as a mentor for you, Abhishek. I really enjoyed talking to you guys about both aspects here today and hopefully we will see more of your work, Abhishek and Salvador, as far as understanding the transcriptomic heterogeneity in neuroendocrine tumors or neuroendocrine cancers of the bladder. Dr. Salvador Jaime-Casas: Thank you very much. Thank you for having us. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Do not forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Dr. Abhishek Tripathi Disclosures Consulting or Advisory Role:  Company: Aadi biosciences, Seattle Genetics/Astellas, Exelixis, Bayer, Gilead Sciences, Pfizer, Deka biosciences Speakers' Bureau: Company: Sanofi

Here they come again! Another far-right-wing mob, spurred on by Trump, is storming our US Capitol!Only, these are not uncouth MAGA marauders wearing buffalo horns, breaking in, and attacking Capital police. No, this is a very couth, richly-attired, well-mannered political mob laying siege on Congress. And look: Instead of fighting or fleeing, Republican lawmakers are holding the Capitol's doors wide open for this incursion! That's because this is a swarm of always-welcome corporate lobbyists and campaign funders. In particular, they're an army of global pesticide giants.Led by Bayer, the multibillion-dollar German biochemical conglomerate, they're demanding that Congress keep us commoners from interfering with their poisonous profiteering. Bayer reaps billions of dollars selling a killer pesticide named Roundup, which scientists increasingly consider a cause of cancer, especially in children. Thousands of afflicted families have filed major lawsuits holding Bayer responsible.Of course, Bayer honchos did the honorable thing. Ha! Just kidding. Instead, its lobbyists rushed to Trump and GOP congressional leaders, who – shhhh – quietly tucked a corporate “gotcha” into this month's must-pass budget bill. It would effectively hand retroactive immunity to chemical manufacturers, quashing all those lawsuits filed by families of Roundup victims. Sneaky, huh? Infuriated, grassroots leaders of MAHA (The “Make America Healthy Again” movement) say the Republican Party is being corrupted by false information from the pesticide companies.This is Jim Hightower saying… Actually, what's corrupting the Party's lawmakers is the gusher of campaign money they take from the poison pushers. For information and action on stopping this capitulation to what a Bayer, go to FoodAndWaterWatch.org.Jim Hightower's Lowdown is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit jimhightower.substack.com/subscribe

I never thought you could earn from somebody else's settlements.But our guest today, Patrick Grimes, introduced us to another (“unique”, I would say) #alternativeinvestment that isn't mainstream yet.- AxelEpisode Takeaway and Action PlanEpisode Highlights:[00:00:00-00:02:06] From Tesla to Real Estate[00:02:07-00:04:24] Beyond the Stock Market[00:04:25-00:15:20] A Unique Opportunity with Legal Funding[00:15:21-00:19:29] Risks in Litigation Funding?[00:19:30-00:27:21] The Case for Diversification[00:27:22-00:31:23] How to Become a Litigation Investor[00:31:24-00:37:20] Behind the Scenes at SpaceX and TeslaSpecial Mentions:* Tesla, SpaceX, Bayer, Monsanto, Lockheed, Raytheon, Abbott, J&J, 3M, DuPont, Lessons from Thought Leaders by Patrick Grimes, Phil Collins, Def Leppard, Kevin Eastman, Zig Ziglar, and Brian Tracy* Cases mentioned: Camp Lejeune water contamination, LA Juvenile Detention Center sexual assault, Roundup/paraquat lawsuits, toxic baby formula***Start taking action right NOW! 

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über die große Parkinson-Wette von Bayer, den BYD-Abschied von Warren Buffett und die unglaubliche Mag7-Bilanz. Außerdem geht es um Pfizer, Metsera, Eli Lilly, Novo Nordisk, Porsche Automobil Holding SE, Porsche AG, Volkswagen, Berkshire Hathaway, BYD, Taiwan Semiconductor, Amundi MSCI USA Daily (2x) Leveraged ETF (WKN: A0X8ZS), WisdomTree Nasdaq 100 3x Daily Leveraged ETP (WKN: A3GL7E), WisdomTree Dax 3x Daily Leveraged ETP (WKN: A1VBKS), Invesco Nasdaq 100 (WKN: 801498). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Samstagnachmittag, 15:30 Uhr – der FC St. Pauli empfängt Bayer 04 Leverkusen. Ein Podcast über ein Trainer-Missverständnis, einen elementaren Kaderumbruch und über Perspektivspieler.

Nina, Tim und Maik besprachen die Niederlage beim VfB Stuttgart, die furchtbarsten Torjingles der Liga, die Niederlage der 1. Frauen in Aurich und die anstehende Redaktionswoche vor dem Spiel gegen Bayer 04 Leverkusen.

Eugen Polanskis Borussia hat den Fans einen Moment der Ekstase beschert beim 1:1 bei Bayer 04 Leverkusen. Unsere Reporter ordnen das erste Spiel des Trainers in all seinen Facetten ein und besprechen die Weichenstellungen für die Zukunft, die sonst noch anstehen in Gladbach.

Bayer setzt auf eine neue Gen- und Zelltherapie. Die Chancen für die Marktreife des Medikaments stehen laut Analysten 50:50. Außerdem: die besten Angebote für Tagesgeld.

Bill Anderson joins Around the Farm to discuss all things Bayer including trust, innovation and how FieldView & Preceon are shaping agriculture's future. In this episode, Bill Anderson shares what he's learned during his first year leading Bayer AG and how the company is evolving to meet the needs of today's growers. From Dynamic Shared Ownership to the launch of Preceon Smart Corn System, he outlines how Bayer is creating value across the ag ecosystem. Bill also addresses topics like Roundup litigation, public perception of big ag, and the role of digital farming tools like FieldView. Whether you're a grower, advisor, or just curious about Bayer's vision for the future, this episode offers direct insight from the top.

I never thought you could earn from somebody else's settlements. But our guest today, Patrick Grimes, introduced us to another (“unique”, I would say) #alternativeinvestment that isn't mainstream yet.Episode Deep Dive with Action Plan: https://tinyurl.com/ep-joe-tegtmeyerEpisode Highlights:[00:00:00-00:02:06] From Tesla to Real Estate[00:02:07-00:04:24] Beyond the Stock Market[00:04:25-00:15:20] A Unique Opportunity with Legal Funding[00:15:21-00:19:29] Risks in Litigation Funding?[00:19:30-00:27:21] The Case for Diversification[00:27:22-00:31:23] How to Become a Litigation Investor[00:31:24-00:37:20] Behind the Scenes at SpaceX and TeslaSpecial Mentions:Tesla, SpaceX, Bayer, Monsanto, Lockheed, Raytheon, Abbott, J&J, 3M, DuPontLessons from Thought Leaders by Patrick Grimes, Phil Collins, Def Leppard, Kevin Eastman, Zig Ziglar, and Brian TracyCases mentioned: Camp Lejeune water contamination, LA Juvenile Detention Center sexual assault, Roundup/paraquat lawsuits, toxic baby formula***Start taking action right NOW! 

All these questions are on make believe places! LOVE TRIVIA WITH BUDDS? CHECK OUT THE MNEMONIC MEMORY PODCAST!  “Grow your brain one leaf at a time—tune in to The Mnemonic Memory Podcast.” http://www.themnemonictreepodcast.com/ Fact of the Day: Heroin was once marketed and sold by Bayer as a non-addictive cough medicine. Triple Connections: Teri Garr, Gene Wilder, Peter Boyle THE FIRST TRIVIA QUESTION STARTS AT 01:29 SUPPORT THE SHOW MONTHLY, LISTEN AD-FREE FOR JUST $1 A MONTH: www.Patreon.com/TriviaWithBudds INSTANT DOWNLOAD DIGITAL TRIVIA GAMES ON ETSY, GRAB ONE NOW!  GET A CUSTOM EPISODE FOR YOUR LOVED ONES:  Email ryanbudds@gmail.com Theme song by www.soundcloud.com/Frawsty Bed Music:  "EDM Detection Mode" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ http://TriviaWithBudds.com http://Facebook.com/TriviaWithBudds http://Instagram.com/ryanbudds Book a party, corporate event, or fundraiser anytime by emailing ryanbudds@gmail.com or use the contact form here: https://www.triviawithbudds.com/contact SPECIAL THANKS TO ALL MY AMAZING PATREON SUBSCRIBERS INCLUDING:   Mollie Dominic Vernon Heagy Brian Clough Nathalie Avelar Becky and Joe Heiman Natasha raina Waqas Ali leslie gerhardt Skilletbrew Bringeka Brooks Martin Yves Bouyssounouse Sam Diane White Youngblood Evan Lemons Trophy Husband Trivia Rye Josloff Lynnette Keel Nathan Stenstrom Lillian Campbell Jerry Loven Ansley Bennett Gee Jamie Greig Jeremy Yoder Adam Jacoby rondell Adam Suzan Chelsea Walker Tiffany Poplin Bill Bavar Sarah Dan  Katelyn Turner Keiva Brannigan Keith Martin Sue First Steve Hoeker Jessica Allen Michael Anthony White Lauren Glassman Brian Williams Henry Wagner Brett Livaudais Linda Elswick Carter A. Fourqurean KC Khoury Tonya Charles  Justly Maya Brandon Lavin Kathy McHale Chuck Nealen Courtney French Nikki Long Mark Zarate Laura Palmer  JT Dean Bratton Kristy Erin Burgess Chris Arneson Trenton Sullivan Jen and Nic Michele Lindemann Ben Stitzel Michael Redman Timothy Heavner Jeff Foust Richard Lefdal Myles Bagby Jenna Leatherman Albert Thomas Kimberly Brown Tracy Oldaker Sara Zimmerman Madeleine Garvey Jenni Yetter JohnB Patrick Leahy Dillon Enderby James Brown Christy Shipley Alexander Calder Ricky Carney Paul McLaughlin Casey OConnor Willy Powell Robert Casey Rich Hyjack Matthew Frost Brian Salyer Greg Bristow Megan Donnelly Jim Fields Mo Martinez Luke Mckay Simon Time Feana Nevel

Bayer Crop Science is rolling out a new version of Raxil seed treatment as the cereal protection product continues to evolve after 25 years in the marketplace. Raxil Rise — new for 2026 — will give growers better broad spectrum seed-and soil-borne disease control thanks to the addition of penflufen for enhanced protection against yield-robbing... Read More

Eintracht Frankfurt ballert sich auf Champions League Platz 1! Bayer Leverkusen nimmt einen Punkt aus Kopenhagen mit und Europameister Thomas Helmer blickt mit André auf den 4. Spieltag in der Bundesliga.

A special thank you to PaleoLady for our new theme music! Toay we talk about some naughty naughty Nazi collaborating corporations, among other things...If you want to listen ad-free, check out our substack at hemisphericpress.substack.com. If you'd like to publish a book with us, please email hemisphericpress@gmail.com or submit a sample chapter to editor@hemisphericpress.com

EASY LISTENING DEP'T.: It's one thing to ruin the lives of civil servants, it's quite another to inconvenience Bayer. Please visit, read, and support INDIGNITY! https://www.indignity.net/

Christopher Kinsey has been named a Beck's Player with Heart due to his dedication to his school, community, and the agriculture industry. To Christopher, agriculture is family, tradition, and the values that come from working with your hands and caring for something bigger than yourself. Being involved in the agriculture industry has allowed him to find patience when waiting for a crop to grow, pride in seeing the results of that work, and gratitude for the people who make it possible. It represents hard work, responsibility, and the connection we all share with the land and the food we eat. Christopher is currently a captain on his school's football team, saying that the camaraderie between my brothers on the field is something that happens once in a lifetime. The friendships, the hardships, and everything else in between are what he loves most about being a part of a team. Christopher is also the president of his FFA chapter this year. He says he is happy to be part of the behind the scenes of these activities, which is what makes these programs special. Christopher is passionate about being there for his community when he can, as he is currently serving as a cadet fireman at his local fire department. After high school, Christopher plans to continue his education with the fire program and attend EMT school to become a full-time fireman/paramedic.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Da platzt eine Breaking News direkt in den BOHNDESLIGA-freien Montag rein! KASPER HJULMAND wird neuer Trainer von BAYER LEVERKUSEN. Das kommt durchaus überraschend, schließlich hat Hjulmand seit über zehn Jahren nicht mehr in der BUNDESLIGA gearbeitet. Wie ist dieser Transfer zu bewerten? Die BOHNDESLIGA-Crew aus Nils, Etienne, Tobi und Niko bewerten den Wechsel. Tobi erläutert, wie Hjulmand als dänischer Nationaltrainer hat spielen lassen. Etienne wirft ein paar andere Trainerkandidaten in den Raum, während Niko die kreative LEVERKUSENer Führung lobt. Wird Hjulmand die WERKSELF in die gelobte CHAMPIONS LEAGUE führen? Bleibt er länger im Sattel als Erik ten Hag? Diese und viele andere Fragen beantworten wir im BOHNDESLIGA-Special!

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Meet Mina Hoshizawa, a dynamic in-house legal counsel who has built her career on adaptability and genuine connection. Now leading legal and compliance functions at Nihon Servier, she shares candid insights about unlearning perfectionism, embracing vulnerability as a leadership strength, and why being fluid like water has been her career superpower. If you are considering the transition to an in-house position or thinking you might skip the law firm experience and focus on in-house, this is the episode for you. If you enjoyed this episode and it inspired you in some way, we'd love to hear about it and know your biggest takeaway. Head over to Apple Podcasts to leave a review and we'd love it if you would leave us a message here!In this episode you'll hear:Why even practical motivations can lead to passionate careersThe art of "unlearning" from private practice what lawyers must focus on to win at in-house roles Her vulnerable leadership approach and what she often says to her teamPractical strategies for establishing legal functions from zero Where to look for opportunities if you intend to skip the law firm experienceAbout MinaMina Hoshizawa is Head of Legal and Compliance at Servier in Japan, sitting on the Leadership Team. Before joining Servier, she belonged to Bayer in Japan and served as Compliance Manager for the entire company and as Legal Manager for its Consumer Health Business and Crop Science Business. Mina is a qualified Japanese bengoshi (attorney), and before joining Bayer, she worked at Freshfields' Tokyo office. She is the leader of a working group of the Governance and Legal Committee of The European Federation of Pharmaceutical Industries and Associations (EFPIA). She was selected as LexisNexis® UNDER 40 2024, Japan Rising Star 2024 by GC Powerlist Legal 500, and became the first JILA In-house award winner in the Compliance category in Individual Awards 2023.In her free time Mina likes to play badminton with her daughter. Connect with Mina LinkedIn: https://www.linkedin.com/in/mina-hoshizawa-76ab01262/ Connect with Catherine LinkedIn https://www.linkedin.com/in/oconnellcatherine/Instagram: https://www.instagram.com/lawyeronair

This week's agriculture news highlights policy developments as Congress returns to session, including updates on labor, environmental regulations and water policy. We also bring insights from Bayer Crop Science on the future of short corn. A federal district court in Louisiana recently vacated part of the 2023 Adverse Effect Wage Rate Rule, specifically the H-2A disaggregation provision. Meanwhile, the Environmental Protection Agency has withdrawn proposed revisions to wastewater regulations for meat and poultry processors. Looking ahead, the Trump administration is preparing to propose a new Clean Water Act rule in the coming weeks. Additional reports point to a projected increase in U.S. net farm income in 2025, along with new insights on ag export trends. A conversation on the future of short corn, in addition to what it provides to growers, is this week's interview with two voices from Bayer Crop Science: NA Technical Product Lead for Preceon™ Devin Hammer and Digital Enablement Product Lead Andy Folta. They share how shorter, thicker stalks benefit the plant, the length of time Bayer has been testing the Preceon™ Smart Corn System, and how short corn can also be utilized for silage. This discussion took place at the recent Farm Progress Show with Ag News Daily Co-Host Tanner Winterhof. Stay connected with us for more agriculture content on Instagram, TikTok, Facebook, and YouTube, along with our weekly videos! ALWAYS READ AND FOLLOW IRM, WHERE APPLICABLE, GRAIN MARKETING AND ALL OTHER STEWARDSHIP PRACTICES AND PESTICIDE LABEL DIRECTIONS. ©2025 Bayer Group. All rights reserved.

As if anyone cares on todays show we talk about Monsanto, Roundup, GMOs, Agent Orange, carcinogen, Bayer acquisition, lawsuits, non-Hodgkin lymphoma, seed patents, crop drift, government agencies, chemical herbicides, organic farming, Monsanto strategy, legal battles., Roundup, chemical alternatives, Epsom salts, FDA approved, natural methods, leukemia, paint stores, weed eater, garden implements, ALAR, coffee, PJs coffee, Second Round Bakery, podcast, Washington DC.

The planet Jupiter will slide past one of the brighter stars of Gemini the next few mornings. At their closest, they’ll be separated by just a fraction of a degree. The star is Wasat – from an Arabic phrase that means “the middle.” But the middle of what has been lost over the centuries. The star also is known as Delta Geminorum – its Bayer designation. The system was devised in the early 17th century by German astronomer Johann Bayer. He named all of the stars in the constellations that were visible from the northern hemisphere. Each star was given a Greek letter followed by the constellation name. If he ran out of letters, he switched to the Latin alphabet. In most constellations, Bayer named the stars in the order of their brightness. The brightest was alpha, the next-brightest was beta, and so on. Sometimes, he ranked the stars on their location or some other system. And he named the stars based on how they looked to the naked eye, so the rankings were completely subjective. So even though delta is the fourth letter in the Greek alphabet, Delta Geminorum is only the eighth-brightest star in Gemini. Jupiter and Wasat are well up in the east at dawn. Jupiter looks like a brilliant star, far to the upper right of even-brighter Venus. Wasat will stand below Jupiter tomorrow. Jupiter will drop past it over the following couple of days, so they’ll be at their closest on Saturday and Sunday. Script by Damond Benningfield

Love In Fiction. Emo hyme conductor, sunshine post-pop visionary and silver balloon gift-giver, Phil Bayer, is our guest on Episode 354 of Sappenin' Podcast! The FLOYA vocalist exclusively reveals secrets on the bands newly embraced live reputation, getting a second chance to pursue music and the heartwarming storyboard leading to their double collaboration with Grumble Bee and Airports. In this conversation, Bayer opens up on evolving from the metalcore scene to capturing summer dopamine audio, turning writing trips into exotic creative adventures, establishing unexpected German cult followings in Japan, Australia and Europe, why he almost stepped away from the industry all together, privately auditioning for Marvs ex-band ALAZKA, ego-shattering reviews vs finding his voice, laugh out loud tour memes, awkward venues, Radar Festival reviews, new music plans, hearing the taste of ejaculation and more! Turn it up and join Sean and Morgan to find out Sappenin' this week!Follow us on Social Media:Twitter: @sappeninpodInstagram: @sappeninpodSpecial thank you to our Sappenin' Podcast Patreons:Join the Sappenin' Podcast Community: Patreon.com/Sappenin.Kylie Wheeler, Janelle Caston, Paul Hirschfield, Tony Michael, Scarlet Charlton, Dilly Grimwood, Mitch Perry, Nathan Crawshaw, Molly Molloy, James Bowerbank, Amee Louise, Kat Bessant, Kieran Lewis, Alexandra Pemblington, Jonathan Gutierrez, Jenni Robinson, Stuart McNaught, Jenni Munster, Louis Cook, Carl Pendlebury, James Mcnaught, Martina McManus, Jason Heredia, John&Emma, Danny Eaton, RahRah James, Sian Foynes, Evan, Ollie Amesbury, Dan Peregreen, Emily Perry, Kalila Keane, Adam Parslow, Josh Crisp, Vicki Henshaw, Laura Russell, Fraser Cummings, Sophie Ansell, Kyle Smith, Connor Lewins, Billy Hunter, Harry Radford, George Evans, Em Evans Roberts, Thomas O'Neill, Sinead O'Halloran, Kael Braham, Jade Austin, Charlie Wood, Aurora Winchester, Jordan Harris, James Page, Georgie Hopkinson, Helen Anyetta, John Wilson, Lisa Sullivan, Ayla Emo, Kelly Young, Jennifer Dean, Tj Ambler-Shattock, Chaz Howkins, Michael Snowden, Justine Baddeley, David Winchurch, Jim Farrell, Scott Evans, Andrew Simpson, Shaun Croucher, Lewis Sluman, Ellie Gowers, Luke Wardle, Grazyna McGroarty, Nathan Matheson, Matt Roberts, Joshua Lewis, Erin Howard,, Chris Harris, Lucy Neill, Amy Thomas, Jessie Hellier, Stevie Burke, Robert Pike, Anthony Matthews, Samantha Neville, Sarah Maher, Owen Davies, Bethan Downing, Jessica Tiernan, Danielle Oldershaw, Samantha Bowen, Ruby Price, Jule Ferl, Alice Wood, Billy Parmiter, Emma Musgrave, Rhian Friggens, Hannah Kenyon, Patrick Floyd, Hayley Taylor, Loz Sanchez, Cerys Andrews, Dan Johnson, Eva B, Emma Barber, Helen Macbeth, Melissa Mercury, Joshua Ryan, Cate Stevenson, Emily Moorhouse, Jacob Turner, Madeleine Inez, Robert Byrne, Christopher Goldring, Chris Lincoln, Beth Gayler, Lesley Dargie-Walker, Sabina Grosch, Tom Hylands, Andrew Keech, Kerry Beckett, Leanne Gerrard, Ieuan Wheeler, Hannah Rachael, Gemma Graham, Andy Wastell, Jay Smith, Nuala Clark, Liam Connolly, Lavender Martin, Lloyd Pinder, Ghostly Grimoire, Amy Hogg.Diolch and Thank You x Hosted on Acast. See acast.com/privacy for more information.

TT: The Companies That Own it All: Part 2 In this show, the teenagers (Deven and Ethan) talk about how most of the news networks, defense manufacturers, and more are owned by BlackRock, Vanguard, and State Street. As well as how BlackRock, Vanguard, and State Street own large shares in Bayer, as well as most of the other large companies that are well known and very powerful. How much power do these 3 companies (BlackRock, Vanguard, and State Street) have? This is part 2 in the series of The Companies that own it all. Sponsors: American Gold Exchange Our dealer for precious metals & the exclusive dealer of Real Power Family silver rounds (which we finally got in!!!). Get your first, or next bullion order from American Gold Exchange like we do. Tell them the Real Power Family sent you! Click on this link to get a FREE Starters Guide. Abolish Property Taxes in Ohio: https://reformpropertytax.com/ Our Links: www.RealPowerFamily.com Info@ClearSkyTrainer.com 833-Be-Do-Have (833-233-6428)

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über Aktien mit Achterbahn-Potenzial, die nächste BYD-Schlappe und das Ende der Stada-Hoffnungen. Außerdem geht es um Rheinmetall, Renk, Hensoldt, Sartorius, Commerzbank, E.on, Siemens Energy, Bayer, TeamViewer, Strategy, Ceconomy, JD.com, The Walt Disney Company, Six Flags Entertainment, Cedar Fair Entertainment Company, United Parks & Resorts, Mitsui Fudōsan, iShares STOXX Europe 600 Travel & Leisure (A0H08S). Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

https://www.youtube.com/watch?v=F6vA9ensrzw Podcast audio: In this episode of The Ayn Rand Institute Podcast, Ben Bayer and Nikos Sotirakopoulos critique a recent Wall Street Journal article that tries to explain Zohran Mamdani's rise and the persistence of socialism in American politics. Among the topics covered: Why socialism is not an innate impulse or the product of ignorance of history; Why idealism alone does not explain socialism's popularity; How miseducation about capitalism contributes to the endurance of socialism; Why you can't fight woke ideology while upholding Christianity's altruistic ethic; How to defeat socialism. Recommended in this podcast are Ayn Rand's Atlas Shrugged, her article “Faith and Force: The Destroyers of the Modern World,” the Ayn Rand Lexicon entry on Socialism, and Bayer's articles “The Dishonesty of ‘Real Socialism Has Never Been Tried'” and “The Old Morality of the New Religions.” The podcast was recorded on August 25, 2025 and posted on August 28, 2025. Listen and subscribe wherever you get your podcasts. Watch archived podcasts here.

[01:02:09] Conservatives Back Martial LawOpening monologue criticizes conservatives for supporting Trump's talk of deploying troops in U.S. cities, linking it to the Pentagon's long-term planning for urban control. [01:05:31] Prohibition, Cartels & TerrorComparison of alcohol prohibition to the drug war; warns that attacking Mexican cartels militarily could spark terrorism inside American cities and provide cover for martial law. [01:12:29] Election Rigging & GerrymanderingDiscussion of how both parties manipulate elections through gerrymandering and voting controls; frames Trump as a Pentagon puppet in a larger plan of urban militarization. [01:20:48] Conservatives Cheer MilitarizationChicago carjacking victim opposed National Guard deployment; conservatives attacked her online, showing how Trump has shifted the right to embrace authoritarian solutions. [01:29:46] Normalizing Martial LawAnalysis of how deploying troops in D.C. and other cities is “predictive programming” to normalize military presence and condition officials and citizens for broader martial law. [01:45:21] Democrats Only OppositionClosing reflections argue conservatives have abandoned constitutional limits, leaving only Democrats to oppose Trump's martial law plans—though they oppose for the wrong reasons, focusing only on partisan power. [02:19:39] Texas “Big Beautiful Map” & Election RiggingDiscussion of Texas Senate passing a gerrymandered redistricting bill, Trump pushing to ban mail-in ballots and voting machines, and how both parties manipulate elections. [02:32:18] CDC Launches Vaccine Injury ReviewCriticism of the CDC forming a group to investigate COVID vaccine injuries, framed as a whitewash to protect Trump's Operation Warp Speed and Big Pharma. [02:36:04] Genetic Code Injections & Aluminum RisksSegment highlights concerns over mRNA shots replicating uncontrollably and reviews studies linking aluminum adjuvants to asthma, autism, and SIDS. [02:43:09] Hypervaccination Horror StoriesPersonal accounts of children permanently damaged after “catch-up” vaccine schedules in custody battles; broader attack on CDC and medical industry dishonesty. [02:49:41] Bioweapon Narrative & Military OperationDiscussion frames COVID vaccination as a Pentagon/DARPA military operation, not medicine, with secrecy and top-secret clearances tied to bio-surveillance. [03:08:15] Bayer, Monsanto & Legal ImmunityDeep dive into Monsanto's history with Agent Orange, PCBs, Roundup, GMOs, and Bayer's Nazi past; warnings that Trump and RFK Jr. are paving the way for legal immunity for “Big Pest.” [03:30:29] Greenland Child Seizures & Parenting TestsCase of a Greenlandic mother losing her baby under “parenting competence tests,” framed as government overreach tied to globalist family-erasure agendas. [03:35:02] Miraculous Cardiac RecoveryTeen athlete suffers sudden cardiac arrest and survives after 30 minutes without a heartbeat, presented as both a vaccine injury suspicion and a story of prayer and divine healing. [03:38:13] Legacy of James DobsonReflection on the life and influence of James Dobson—praised for defending families but criticized for Zionism and naïve trust in government institutions. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:02:09] Conservatives Back Martial LawOpening monologue criticizes conservatives for supporting Trump's talk of deploying troops in U.S. cities, linking it to the Pentagon's long-term planning for urban control. [01:05:31] Prohibition, Cartels & TerrorComparison of alcohol prohibition to the drug war; warns that attacking Mexican cartels militarily could spark terrorism inside American cities and provide cover for martial law. [01:12:29] Election Rigging & GerrymanderingDiscussion of how both parties manipulate elections through gerrymandering and voting controls; frames Trump as a Pentagon puppet in a larger plan of urban militarization. [01:20:48] Conservatives Cheer MilitarizationChicago carjacking victim opposed National Guard deployment; conservatives attacked her online, showing how Trump has shifted the right to embrace authoritarian solutions. [01:29:46] Normalizing Martial LawAnalysis of how deploying troops in D.C. and other cities is “predictive programming” to normalize military presence and condition officials and citizens for broader martial law. [01:45:21] Democrats Only OppositionClosing reflections argue conservatives have abandoned constitutional limits, leaving only Democrats to oppose Trump's martial law plans—though they oppose for the wrong reasons, focusing only on partisan power. [02:19:39] Texas “Big Beautiful Map” & Election RiggingDiscussion of Texas Senate passing a gerrymandered redistricting bill, Trump pushing to ban mail-in ballots and voting machines, and how both parties manipulate elections. [02:32:18] CDC Launches Vaccine Injury ReviewCriticism of the CDC forming a group to investigate COVID vaccine injuries, framed as a whitewash to protect Trump's Operation Warp Speed and Big Pharma. [02:36:04] Genetic Code Injections & Aluminum RisksSegment highlights concerns over mRNA shots replicating uncontrollably and reviews studies linking aluminum adjuvants to asthma, autism, and SIDS. [02:43:09] Hypervaccination Horror StoriesPersonal accounts of children permanently damaged after “catch-up” vaccine schedules in custody battles; broader attack on CDC and medical industry dishonesty. [02:49:41] Bioweapon Narrative & Military OperationDiscussion frames COVID vaccination as a Pentagon/DARPA military operation, not medicine, with secrecy and top-secret clearances tied to bio-surveillance. [03:08:15] Bayer, Monsanto & Legal ImmunityDeep dive into Monsanto's history with Agent Orange, PCBs, Roundup, GMOs, and Bayer's Nazi past; warnings that Trump and RFK Jr. are paving the way for legal immunity for “Big Pest.” [03:30:29] Greenland Child Seizures & Parenting TestsCase of a Greenlandic mother losing her baby under “parenting competence tests,” framed as government overreach tied to globalist family-erasure agendas. [03:35:02] Miraculous Cardiac RecoveryTeen athlete suffers sudden cardiac arrest and survives after 30 minutes without a heartbeat, presented as both a vaccine injury suspicion and a story of prayer and divine healing. [03:38:13] Legacy of James DobsonReflection on the life and influence of James Dobson—praised for defending families but criticized for Zionism and naïve trust in government institutions. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Sentera: https://sentera.com/Chandler Coop: https://www.chandlercoop.com/Today's episode is another installment in our Tech-Enabled Advisor series. The idea here is to better understand agtech through the lens of the BUYER and USER of that technology rather than just the entrepreneurs or investors behind it. I've received some super positive feedback about the return of this series. By talking to the buyers rather than the sellers of the tech, we got an unfiltered introduction to the technology and more importantly got to see HOW its used and the VALUE that it provides. To do this, I partner with a company and together we invite one of their customers onto the show. The catch is that they're not allowed to script these individuals or dictate what to say or edit it after it is recorded - it has to be real and unfiltered. So today's episode featuring Nick Einck of Chandler Coop is produced in partnership with Sentera. Sentera is a leading provider of remote imagery solutions. Their industry-leading cameras are compatible with most major drone platforms and enable farmers and crop scouts to efficiently capture high-resolution data. Their capabilities and FieldAgent software tools help farmers and agronomists assess plant-level health, identify stressors, and take action. Also their customized herbicide prescription, SMARTSCRIPT™ Weeds, can be delivered to sprayers with individual nozzle control.So drones equipped with Sentera technology fly over fields at high speeds and generate high-resolution images. The images are processed using proprietary deep learning algorithms to identify the exact location of specific weeds and generate a weed map. This map becomes a targeted prescription for how much product a farmer needs to load into their sprayer, saving money and minimizing waste. This past May, John Deere announced they were acquiring Sentera.So I'm very excited to partner with them for this episode, which is a fantastic deep dive into how innovative technology like this combined with something like See-and-Spray really changes the game.Some background on Nick before we dive in: Nick Einck is the Director of Agronomy at Chandler Co-op, a farmer-owned cooperative serving more than 900 customers and providing agronomic services across over 100,000 acres in southwest Minnesota. He began his career at Chandler as an intern and seed manager before spending nearly a decade with Monsanto and Bayer, gaining deep expertise in agronomy, product development, and grower engagement across the Midwest. Nick returned to Chandler in October 2024, bringing both retail and industry experience to help advance the co-op's agronomic strategy. Today, he leads a multi-location agronomy team focused on leveraging tech-enabled tools—like SmartScript™—to help growers make faster, more informed decisions and drive greater return from every acre.